News - Vectura

Filter

Current filters:

Vectura

Popular Filters

1 to 25 of 33 results

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

Vectura sees hefty rise in full-year 2013/14 revenues, as loss narrows

21-05-2014

Shares of UK developer of inhaled therapies Vectura gained 3.1% to 131.45 pence in early trading this…

FinancialPharmaceuticalRespiratory and PulmonaryVectura

Vectura to buy Germany’s Activaero for 130 million euros

Vectura to buy Germany’s Activaero for 130 million euros

14-03-2014

UK developer of inhaled therapies Vectura says it is acquiring privately-held German company Activaero…

ActivaeroFinancialMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

19-12-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

Vectura appoints ex-AstraZeneca VP Bruno Angelici as non-executive chairman

Vectura appoints ex-AstraZeneca VP Bruno Angelici as non-executive chairman

20-11-2013

UK-based developer of inhaled therapies Vectura Group (LSE: VEC) has announced the appointment of Bruno…

BoardroomEuropeUKVectura

Vectura posts flat sales and increased loss for first-half 2013

19-11-2013

UK-based developer of inhaled therapies Vectura Group has announced its unaudited interim results for…

FinancialNovartisPharmaceuticalRespiratory and PulmonaryVectura

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Further evidence of Ultibro Breezhaler efficacy showcased at ERS meeting

09-09-2013

Swiss drug major Novartis (NOVN: VX) released date data from new analyses for once-daily Ultibro Breezhaler…

NovartisPharmaceuticalResearchRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Vectura foresees important catalysts in second half

13-08-2013

Shares of UK-based developer of inhaled therapies Vectura (LSE: VEC) rose 1.6% to 96 pence in mid-morning…

EuropeFinancialPharmaceuticalRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Vectura anticipates potential royalty and milestone payments on Fibrocaps

06-08-2013

UK-based developer of inhaled therapies Vectura (LSE: VEC) confirms that the completion of the acquisition…

FibrocapsFinancialPharmaceuticalProFibrixResearchThe Medicines CompanyVectura

Two CHMP positives for Novartis

29-07-2013

There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro BreezhalerVectura

Ockham Biotech prevails in Vectura's patent challenge for inhaled heparin in COPD

03-06-2013

UK-based Ockham Biotech says that its European patent covering the use of inhaled heparin for the treatment…

BiotechnologyEuropeheparinOckham BiotechPatentsRespiratory and PulmonaryVectura

Vectura fiscal 2012/13 revenues beat own expectations, and loss narrows

21-05-2013

UK inhaled therapies developer Vectura Group (LSE: VEC) yesterday presented its preliminary results for…

FinancialManagementPharmaceuticalVectura

Citi upbeat on Vectura; S&P's upgrades Merck KGaA

02-12-2012

ecember 3, 2012 In a report issued last week on UK drug delivery specialties Vectura (LSE: VEC), analysts…

FinancialMerck KGaAPharmaceuticalVectura

Vectura first-half 2012 revenues down but now set for next growth phase

21-11-2012

UK inhaled therapies developer Vectura (LSE: VEC) saw its shares dip 1.9% to 78.50 pence in early afternoon…

FinancialPharmaceuticalVectura

New data from Novartis on QVA149 and Seebri Breezhaler at ERS

03-09-2012

Further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs…

NovartisPharmaceuticalQVA149ResearchRespiratory and PulmonarySeebri BreezhalerVectura

Novartis set to file QVA149 filing in EU and Japan by end of year

31-08-2012

Swiss drug major Novartis announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium…

NovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonarySeebri BreezhalerVectura

Credit Suisse focus on new drugs for COPD

19-08-2012

New data will be presented at the European Respiratory Society, due to take place in Vienna, Austria,…

aclidiniumAlmirallGlaxoSmithKlineNovartisPharmaceuticalQVA149ResearchRespiratory and PulmonaryTheravanceVecturaZephyr

Vectura updates on developmental products and milestones

15-08-2012

UK-based Vectura (LSE: VEC) saw its share price rise 4.9% to 75.50 pence yesterday morning, after the…

FinancialPharmaceuticalResearchRespiratory and PulmonarySeebri BreezhalerVectura

1 to 25 of 33 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top